1310569-81-3

Basic information

• Product Name: (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-4-morpholinobutyl oxime
• CAS NO: 1310569-81-3
• Molecular Weight: 458.56
• Mol File: 1310569-81-3.mol

Chemical Properties

• CAS DataBase Reference: (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-4-morpholinobutyl oxime(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-4-morpholinobutyl oxime(1310569-81-3)
• EPA Substance Registry System: (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-4-morpholinobutyl oxime(1310569-81-3)

Safety Data

• Hazardous Substances Data: 1310569-81-3(Hazardous Substances Data)

Upstream product

• 479077-76-4 1-[4-(furo[2,3-b]quinolin-4-ylamino) phenyl]ethanone 

Relevant articles and documents

4-ANILINOFURO[2,3-B]QUINOLINE DERIVATIVES, THEIR PREPARATION PROCESSES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Disclosed herein are novel 4-anilinofuro[2,3-b]quinoline derivatives of formula (I): or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives and their uses in the manufacture of pharmaceutical compositions and in the treatment of cancers.

4-ANILINOFURO[2,3-b]QUINOLINE DERIVATIVES, THEIR PREPARATION PROCESSES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Disclosed herein are novel 4-anilinofuro[2,3-b]quinoline derivatives of formula (I), or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are t

Discovery of 4-anilinofuro[2,3- b ]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers

We have reported the preparation and anticancer evaluation of certain 4-anilinofuro[2,3-b]quinolines. However, drawbacks such as lack of selective cytotoxicity, poor oral bioavailability, and poor water solubility exhibited by these compounds prompted us to search for newer derivatives. Among them, (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-2-aminoethyloxime (13a) is selectively active against the growth of NCI-H460 and is highly water-soluble (63 μg/mL). Its hydrochloride salt, 13a?HCl exhibited not only excellent water solubility (1049 μg/mL) but also a high oral bioavailability (57.1%). Compound 13a may cause cancer cell apoptosis through inducing mitotic arrest and mitotic catastrophe mechanism. Xenographic studies indicated the tumor size with 13a?HCl treated nude mice was significantly lower than control. Further evaluation in an orthotopic lung cancer model indicated that 13a?HCl can be absorbed readily through oral administration, distributed to lung tissue, and exhibited significant efficacy in inhibiting the growth of lung cancers.